Effects of postoperative treatment with chemotherapy and cellular immunotherapy on patients with colorectal cancer

Figure 1 Serum tumor marker levels in the two colorectal cancer treatment groups. The control group was treated with the XELOX chemotherapy regimen and the research group with XELOX + the dendritic cell-cytokine-induced killer immunotherapy regimen. A: Pre- and posttreatment carcinoembryonic antigen levels in the two groups. B: Pre- and posttreatment carbohydrate antigens (CA)19-9 levels in the two groups; C: Pre- and posttreatment CA242 levels in the two groups. ^aP < 0.05 compared to pre-treatment levels; ^bP < 0.01 compared to pre-treatment levels. CEA: Carcinoembryonic antigens; CA: Carbohydrate antigens.

Figure 2 Pre- and posttreatment levels of T-cell subsets in the two colorectal cancer treatment groups. The control group was treated with the XELOX chemotherapy regimen and the research group with XELOX + the dendritic cell-cytokine-induced killer immunotherapy regimen. A: Pre- and posttreatment CD3⁺ levels in the two groups; B: Pre- and posttreatment CD3⁺ CD4⁺ levels in the two groups; C: Pre- and posttreatment CD3⁺ CD8⁺ levels in the two groups; D: Pre- and posttreatment natural killer (NK) cell levels in the two groups; E: Pre- and posttreatment NK T-cell levels in the two groups. ^aP < 0.05 compared to pre-treatment levels; ^bP < 0.01 compared to pre-treatment levels; ^cP < 0.05 compared to control group levels. CD: Cluster of differentiation; NK: Natural killer.